Implantable cardiac monitors provide continuous rhythm monitoring to detect asymptomatic atrial fibrillation recurrences after ablation, though their clinical impact requires prospective evaluation.
Continuous rhythm monitoring with implantable cardiac monitors may improve the detection of asymptomatic atrial fibrillation recurrences after ablation, though its clinical impact requires evaluation in prospective trials.
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia in clinical practice. It is associated with significant morbidity and mortality and has been identified as an independent risk factor for ischemic stroke and thromboembolic events. Catheter ablation has become an established rhythm control therapy in patients with highly symptomatic drug-refractory AF. The definition of ablation success remains controversial since current symptom-based or intermittent electrocardiogram monitoring strategies fail to sufficiently disclose rhythm outcome. This failure is mainly related to the high incidence of asymptomatic AF recurrences, the unpredictable nature of arrhythmia relapses, and the poor correlation of symptoms and AF episodes. There is a clear correlation between the intensity of the monitoring strategy and the sensitivity for it to detect arrhythmia recurrences. Furthermore, several clinical studies assessing the long-term efficacy of catheter ablation procedures have reported late AF recurrences in patients who were initially considered responders to catheter ablation. In certain subsets of patients, precise long-term monitoring may help to guide therapy, e.g. patients in whom withdrawal of antithrombotic therapy may be considered if they are free of arrhythmia recurrences. Recently, subcutaneous implantable cardiac monitors (ICM) have been introduced for prolonged and continuous rhythm monitoring. The performance of a leadless ICM equipped with a dedicated AF detection algorithm has recently been assessed in a clinical trial demonstrating a high sensitivity and overall accuracy for identifying patients with AF. The clinical impact of ICM-based follow-up strategies, however, has to be evaluated in prospective clinical trials.
Kircher et al. (2012) conducted a review in Atrial fibrillation. Implantable cardiac monitors (ICM) was evaluated. Implantable cardiac monitors provide continuous rhythm monitoring to detect asymptomatic atrial fibrillation recurrences after ablation, though their clinical impact requires prospective evaluation.